SCHEMBL328576

SCHEMBL328576

NCCc1cc(O)c(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.62
TAAR1 Q96RJ0 5/20 0.62
KDM4E B2RXH2 4/20 0.62
RECQL P46063 4/20 0.62
MAPK1 P28482 4/20 0.62
ADRA2A P08913 3/20 0.62
SLC6A2 P23975 3/20 0.62
DRD2 P14416 3/20 0.62
DRD1 P21728 3/20 0.62
MAPT P10636 3/20 0.62
APEX1 P27695 3/20 0.62
DRD4 P21917 2/20 0.62
DRD5 P21918 2/20 0.62
DRD3 P35462 2/20 0.62
SLC6A3 Q01959 2/20 0.62
ALDH1A1 P00352 2/20 0.62
HTR1A P08908 2/20 0.62
ALOX15 P16050 2/20 0.62
HSD17B10 Q99714 2/20 0.62
TP53 P04637 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17138365 1.00 TDP1 (0.62) TDP1TAAR1KDM4ERECQLMAPK1
Hydrochloric Acid SCHEMBL3757551 0.97 TDP1 (0.64) TDP1TAAR1KDM4ERECQLMAPK1
Water SCHEMBL17686500 0.97 TDP1 (0.60) TDP1TAAR1KDM4ERECQLMAPK1
Hydrochloric Acid SCHEMBL29134173 0.95 TDP1 (0.58) TDP1TAAR1KDM4ERECQLMAPK1
SCHEMBL69532 0.85 TDP1 (0.54) TDP1TAAR1KDM4ERECQLMAPK1
SCHEMBL20849682 0.84 MAPK1 (0.46) TDP1TAAR1KDM4ERECQLMAPK1
SCHEMBL28735818 0.84 TAAR1 (0.52) TDP1TAAR1KDM4ERECQLMAPK1
SCHEMBL29705208 0.84 TAAR1 (0.52) TDP1TAAR1KDM4ERECQLMAPK1
SCHEMBL10634508 0.84 MAPK1 (0.52) TDP1TAAR1KDM4ERECQLMAPK1
SCHEMBL5495349 0.84 TAAR1 (0.52) TDP1TAAR1KDM4ERECQLMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144903-A1 RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2026-05-28 US claimed
EP-4667020-A1 RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2025-12-24 EP claimed
EP-4667016-A1 BORON-CONTAINING DRUG AND PREPARATION METHOD THEREFOR Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2025-12-24 EP claimed
EP-4088757-B1 PHENOL DERIVATIVE-FUNCTIONALIZED CHONDROITIN SULFATE HYDROGEL AND USE OF SAME CELLARTGEN INC (KR) 2025-12-10 EP claimed
US-12435280-B2 Crude oil demulsifier compositions and uses thereof ECOLAB USA INC. (US) 2025-10-07 US claimed
US-20250114479-A1 TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES (CN) 2025-04-10 US claimed
CN-116516690-B Fiber impregnating solution for improving bonding effect between nylon fiber and rubber and preparation method thereof 青岛科技大学 2025-03-28 CN claimed
US-20250051976-A1 FIBER COMPOSITE STRUCTURE AND MANUFACTURING METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2025-02-13 US claimed
CN-119386268-A In-situ gel forming solution containing polydeoxyribonucleotide as well as preparation method and application thereof 四川兴泰普乐医疗科技有限公司 2025-02-07 CN claimed
CN-117945939-B Bio-based self-assembled amide nucleating agent, and preparation method and application thereof 广东工业大学 2025-01-28 CN claimed
EP-1244435-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES Proteotech Inc. (US) 2002-10-02 EP claimed
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTAMED, INC. 2001-11-29 US claimed
WO-2001049281-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES PROTEOTECH, INC. (US) 2001-07-12 WO claimed
EP-0672148-A1 METHOD FOR MAKING STABLE, EXTRACELLULAR TYROSINASE AND SYNTHESIS OF POLYPHENOLIC POLYMERS THEREFROM Biosource Technologies, Inc. (US) 1995-09-20 EP claimed
US-5340734-A In vitro biosynthesis the melanins in presence of a substrate consisting of tyrosine binding single amino acid, a dipeptide or an oligopeptide BIOSOURCE GENETICS CORPORATION (US) 1994-08-23 US claimed
WO-1994012644-A2 METHOD FOR MAKING STABLE, EXTRACELLULAR TYROSINASE AND SYNTHESIS OF POLYPHENOLIC POLYMERS THEREFROM BIOSOURCE GENETICS CORPORATION (US) 1994-06-09 WO claimed
US-5258427-A MIXTURE OF A LIQUID EPOXY RESIN, A METAL OXIDE AND A POLYHYDROXYARYL COMPOUND ICI AUSTRALIA OPERATIONS PROPRIETARY LTD. (AU) 1993-11-02 US claimed
EP-0458521-A2 Heat curable adhesive ICI AUSTRALIA OPERATIONS PROPRIETARY LIMITED (AU) 1991-11-27 EP claimed
EP-0394983-A2 Anthracycline derivatives with cytostatic activity BEHRINGWERKE Aktiengesellschaft (DE) 1990-10-31 EP claimed
EP-0394982-A2 Anthracycline derivatives with cytostatic activity BEHRINGWERKE Aktiengesellschaft (DE) 1990-10-31 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114479-A1 TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM SLC43A1, LNPEP, TLR3 TDP1 3879/4885TAAR1 1457/4885KDM4E 1745/4885
US-20260144903-A1 RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF DBH, SLC39A11, GHRHR TDP1 3270/4885TAAR1 1206/4885KDM4E 3414/4885
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT TDP1 202/4885TAAR1 536/4885KDM4E 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.